It has been about a month since the last earnings report for Celanese (CE) . Shares have added about 9.6% in that time frame, outperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is Celanese due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers.How Have Estimates Been Moving Since Then?It turns out, ...

It has been about a month since the last earnings report for Hims & Hers Health, Inc. (HIMS) . Shares have added about 10.6% in that time frame, outperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is Hims & Hers Health due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts.How Have Estimates Been M ...

It has been about a month since the last earnings report for Recursion Pharmaceuticals (RXRX) . Shares have added about 5.7% in that time frame, underperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is Recursion Pharmaceuticals due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts.How Have Estimat ...

Core Viewpoint - Guidewire Software reported strong quarterly earnings of $0.88 per share, significantly exceeding the Zacks Consensus Estimate of $0.46 per share, and showing a substantial increase from $0.26 per share a year ago [1][2]. Financial Performance - The company achieved revenues of $293.51 million for the quarter ended April 2025, surpassing the Zacks Consensus Estimate by 2.73% and up from $240.68 million year-over-year [3]. - Guidewire Software has consistently outperformed consensus estimates, surpassing EPS estimates three out of the last four quarters and revenue estimates four times in the same period [2][3]. Stock Performance - Since the beginning of the year, Guidewire Software shares have increased by approximately 27.7%, in contrast to the S&P 500's gain of 0.9% [4]. - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [7]. Future Outlook - The current consensus EPS estimate for the upcoming quarter is $0.59, with projected revenues of $331.29 million, while the estimate for the current fiscal year is $1.97 on revenues of $1.17 billion [8]. - The outlook for the Internet - Software industry is favorable, ranking in the top 22% of over 250 Zacks industries, suggesting potential for outperformance [9].

HealthEquity (HQY) came out with quarterly earnings of $0.97 per share, beating the Zacks Consensus Estimate of $0.81 per share. This compares to earnings of $0.80 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 19.75%. A quarter ago, it was expected that this provider of services for managing health care accounts would post earnings of $0.71 per share when it actually produced earnings of $0.69, delivering a surprise of -2.82 ...

Company Overview - Nurix Therapeutics, Inc. (NRIX) shares increased by 14.2% to close at $12.14, following a period of 5.7% loss over the past four weeks, indicating a significant rebound in stock performance [1][2] Licensing Agreement - Sanofi has exercised its option to exclusively license Nurix's STAT6 program, which includes the development candidate NX-3911, an oral and highly selective STAT6 degrader. Nurix is set to receive a license extension fee of $15 million and is eligible for up to $465 million in potential milestone payments, along with royalties on future sales [2] Financial Expectations - The company is expected to report a quarterly loss of $0.73 per share, reflecting a year-over-year change of -2.8%. Revenue is anticipated to be $17.31 million, representing a 43.2% increase from the same quarter last year [3] Earnings Estimate Revisions - The consensus EPS estimate for Nurix has been revised 1.1% higher over the last 30 days, suggesting a positive trend that may lead to price appreciation in the future [4] Industry Context - Nurix Therapeutics operates within the Zacks Medical - Biomedical and Genetics industry, where another company, Argenx SE (ARGX), saw a 2% increase in its stock price, closing at $584.61, despite a -11.8% return over the past month [4]

Key Takeaways GES expects Q1 sales to rise 5.8-7.5%, signaling wholesale gains in Europe and the Americas. Q1 loss is expected for GES despite revenue growth, as cost pressures and price sensitivity weigh. GES maintains a projected net currency headwind for FY26, with Q1 expected to be the most impacted.Guess?, Inc. (GES) is likely to register top-line growth when it reports first-quarter fiscal 2026 earnings on June 5. The Zacks Consensus Estimate for revenues is pegged at $631 million, implying a 6.6% i ...

Signet (SIG) came out with quarterly earnings of $1.18 per share, beating the Zacks Consensus Estimate of $1.01 per share. This compares to earnings of $1.11 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 16.83%. A quarter ago, it was expected that this jewelry company would post earnings of $6.39 per share when it actually produced earnings of $6.62, delivering a surprise of 3.60%.Over the last four quarters, the company has ...

Red Robin (RRGB) came out with quarterly earnings of $0.19 per share, beating the Zacks Consensus Estimate of a loss of $0.57 per share. This compares to loss of $0.80 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 133.33%. A quarter ago, it was expected that this casual restaurant chain would post a loss of $0.54 per share when it actually produced a loss of $0.94, delivering a surprise of -74.07%.Over the last four quarters ...

It has been about a month since the last earnings report for Ecolab (ECL) . Shares have added about 4.5% in that time frame, underperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is Ecolab due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers.How Have Estimates Been Moving Since Then?It turns out, f ...